GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States.

Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder.

GRI Bio, Inc. was formerly known as Glycoregimmune, Inc.

GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.